SCHEMBL30937745

SCHEMBL30937745

O=C(O)CN1Cc2nc(C(F)(F)F)ccc2NC1=O

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 3/20 0.35
▸ BRS3 P32247 6/20 0.34
▸ ACE P12821 1/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ OTUD7B Q6GQQ9 1/20 0.33
▸ XIAP P98170 1/20 0.32
▸ BIRC2 Q13490 1/20 0.32
▸ POLB P06746 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30937727 0.83 ACE (0.35) ACEMMP13XIAPBIRC2POLB
SCHEMBL30937579 0.80 ACE (0.40) ACEMMP13XIAPBIRC2POLB
SCHEMBL30937575 0.74 GPR139 (0.43) TRPV1
SCHEMBL30937524 0.68 ACE (0.44) ACEMMP13POLBLMNACYP2D6
SCHEMBL30937538 0.68 PER2 (0.45) TRPV1CYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL30937679 0.66 BRD4 (0.51) ACEMMP13POLBCYP2D6CYP2C9
SCHEMBL31120591 0.66 ACE (0.45) ACEMMP13POLBCYP2D6CYP2C9
SCHEMBL30937681 0.66 ACE (0.42) ACEMMP13POLBLMNACYP2D6
SCHEMBL30937651 0.65 ACE (0.53) ACEMMP13POLBLMNACYP2D6
SCHEMBL30937518 0.64 DPP4 (0.38) TRPV1ACEMMP13CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594307-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2025-08-06 — — EP disclosed
WO-2024073426-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
Send feedback